4534 Stock Overview
Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Mochida Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥3,190.00 |
| 52 Week High | JP¥3,745.00 |
| 52 Week Low | JP¥3,055.00 |
| Beta | 0.038 |
| 1 Month Change | 2.57% |
| 3 Month Change | -4.35% |
| 1 Year Change | -8.33% |
| 3 Year Change | -17.25% |
| 5 Year Change | -37.20% |
| Change since IPO | -17.97% |
Recent News & Updates
Mochida Pharmaceutical's (TSE:4534) Dividend Will Be ¥40.00
Mar 22
Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00
Mar 02Shareholder Returns
| 4534 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 1.4% | 4.1% | 1.4% |
| 1Y | -8.3% | 6.9% | 28.4% |
Return vs Industry: 4534 underperformed the JP Pharmaceuticals industry which returned 6.9% over the past year.
Return vs Market: 4534 underperformed the JP Market which returned 28.4% over the past year.
Price Volatility
| 4534 volatility | |
|---|---|
| 4534 Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 4534 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4534's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1913 | 1,529 | Naoyuki Mochida | www.mochida.co.jp |
Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology. It offers Lialda for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Lexapro, an antidepressant drug; Epadel drug for hyperlipidemia and arteriosclerosis obliterans; Urece for the treatment of gout and hyperuricemia; and Treprost for the treatment of pulmonary arterial hypertension.
Mochida Pharmaceutical Co., Ltd. Fundamentals Summary
| 4534 fundamental statistics | |
|---|---|
| Market cap | JP¥113.18b |
| Earnings (TTM) | JP¥3.01b |
| Revenue (TTM) | JP¥100.09b |
37.6x
P/E Ratio1.1x
P/S RatioIs 4534 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4534 income statement (TTM) | |
|---|---|
| Revenue | JP¥100.09b |
| Cost of Revenue | JP¥48.80b |
| Gross Profit | JP¥51.29b |
| Other Expenses | JP¥48.27b |
| Earnings | JP¥3.01b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 13, 2024
| Earnings per share (EPS) | 84.89 |
| Gross Margin | 51.24% |
| Net Profit Margin | 3.01% |
| Debt/Equity Ratio | 0% |
How did 4534 perform over the long term?
See historical performance and comparison